Can Intravitreal Ozurdex Implant Reduce the Incidence of Recurrent Vitreous Hemorrhage After Vitrectomy in Patients with Diabetic Retinopathy?
December 13, 2011
There’s a new clinical trial underway to evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDRP).
The study involves patients that have undergone PPV for vitreous hemorrhage secondary to PDRP. Half of the patients will receive an intravitreal Ozurdex implant immediately after surgery. The primary outcome measure is the proportion of patients that, due to rebleeding within 12 months, have a second PPV. Secondary outcome measures include the number of episodes of vitreous hemorrhage that occur within 12 months after surgery but clear spontaneously.
Click here for further details.
Comments
Jump down to form below to submit your own comments
